Clinical Study for Patients with Metachromatic Leukodystrophy (MLD)

The Embolden Clinical Study is investigating the effects of intrathecal (injection into the spine) administration of their investigational drug (recombinant human arylsulfatase A) compared with matched historical control data in children with MLD. 

Reach out to us if you are interested in learning more about this study and if you meet the following requirements: 

  • Documented diagnosis of MLD
  • Gait disorder attributed to MLD 
  • 18 to 48 months of age 
  • Not enrolled in another clinical study 

Find study specific information at Embolden Study. For general information about MLD visit our Active Trials section.  

Contact us

You can also contact us directly at: 
678 - 883 - 6897
info@rarediseaseresearch.com